In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

Transitioning from second- to third-line therapy
Factors in selecting among available therapies
Key predictors of improved outcomes with regorafenib vs TAS-102

Presenters:

Chiara Cremolini, MD, PhD
Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy

Teresa Macarulla, MD, PhD
Medical Oncologist
Head, Gastrointestinal and Endocrine Tumors Unit
Division of Medical Oncology
Vall d´Hebrón Institute of Oncology
Barcelona, Spain

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Follow along with the slideset:
https://bit.ly/3FjekMo

Link to full program:
https://bit.ly/33yrIyh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer